These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 29719304)

  • 1. Prognostic Value of Soluble Death Receptor Ligands in Patients with Transitional Cell Carcinoma of Bladder.
    Ben Bahria-Sediki I; Chebil M; Sampaio C; Martel-Frachet V; Cherif M; Zermani R; Rammeh S; Ben Ammar Gaaied A; Bettaieb A
    Urol Int; 2018; 100(4):476-484. PubMed ID: 29719304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of bevacizumab on serum soluble FAS/FASL and TRAIL and its receptors (DR4 and DR5) in metastatic colorectal cancer.
    Yildiz R; Benekli M; Buyukberber S; Kaya AO; Ozturk B; Yaman E; Berk V; Coskun U; Yamac D; Sancak B; Uner A
    J Cancer Res Clin Oncol; 2010 Oct; 136(10):1471-6. PubMed ID: 20155284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Significance of serum soluble Fas ligand in patients with bladder carcinoma.
    Mizutani Y; Hongo F; Sato N; Ogawa O; Yoshida O; Miki T
    Cancer; 2001 Jul; 92(2):287-93. PubMed ID: 11466681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Soluble apoptosis molecules in primary biliary cirrhosis: analysis and commitment of the Fas and tumour necrosis factor-related apoptosis-inducing ligand systems in comparison with chronic hepatitis C.
    Pelli N; Floreani A; Torre F; Delfino A; Baragiotta A; Contini P; Basso M; Picciotto A
    Clin Exp Immunol; 2007 Apr; 148(1):85-9. PubMed ID: 17302732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of a combination of soluble Fas and soluble Fas ligand in the serum of patients with Ta bladder cancer.
    Mizutani Y; Yoshida O; Ukimura O; Kawauchi A; Bonavida B; Miki T
    Cancer Biother Radiopharm; 2002 Oct; 17(5):563-7. PubMed ID: 12470426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of soluble tumor necrosis factor-related apoptosis-inducing ligand concentrations after stem cell transplantation.
    Nomura S; Ishii K; Inami N; Uoshima N; Ishida H; Yoshihara T; Kitayama H; Hayashi K
    Transpl Immunol; 2007 Nov; 18(2):115-21. PubMed ID: 18005854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of serum osteoprotegerin levels in patients with bladder carcinoma.
    Mizutani Y; Matsubara H; Yamamoto K; Nan Li Y; Mikami K; Okihara K; Kawauchi A; Bonavida B; Miki T
    Cancer; 2004 Oct; 101(8):1794-802. PubMed ID: 15386310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum soluble Fas ligand (sFasL) in patients with primary squamous cell carcinoma of the esophagus.
    Kozlowski M; Kowalczuk O; Sulewska A; Dziegielewski P; Lapuc G; Laudanski W; Niklinska W; Chyczewski L; Niklinski J; Laudanski J
    Folia Histochem Cytobiol; 2007; 45(3):199-204. PubMed ID: 17951168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased serum sFas, sTRAIL, and reduced sFasL in juvenile-onset systemic lupus erythematosus.
    Liphaus BL; Kiss MHB; Carrasco S; Palmeira P; Goldenstein-Schainberg C; Carneiro-Sampaio M
    Clin Rheumatol; 2017 Dec; 36(12):2847-2852. PubMed ID: 28378099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of soluble Fas in the serum of patients with bladder cancer.
    Mizutani Y; Yoshida O; Bonavida B
    J Urol; 1998 Aug; 160(2):571-6. PubMed ID: 9679930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Change in serum levels of soluble Fas and soluble FasL in patients with multiple organ dysfunction syndrome].
    Fu Y; Xiao QM; Wang T; Chen XH; Ai YH
    Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2006 Nov; 18(11):691-4. PubMed ID: 17092425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fas ligand and TNF-related apoptosis-inducing ligand induction on infiltrating lymphocytes in bladder carcinoma by bacillus Calmette-Guérin treatment.
    Mehmut M; Takeda K; Abe M; Ogata H; Hirose S; Okumura K; Fujime M
    Urol Int; 2005; 75(1):80-7. PubMed ID: 16037714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of TRAIL, DR4, and DR5 in bladder cancer: correlation with response to adjuvant therapy and implications of prognosis.
    Li Y; Jin X; Li J; Jin X; Yu J; Sun X; Chu Y; Xu C; Li X; Wang X; Kakehi Y; Wu X
    Urology; 2012 Apr; 79(4):968.e7-15. PubMed ID: 22244504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating levels of soluble apoptosis-related molecules in patients with multiple sclerosis.
    Moreno M; Sáenz-Cuesta M; Castilló J; Cantó E; Negrotto L; Vidal-Jordana A; Montalban X; Comabella M
    J Neuroimmunol; 2013 Oct; 263(1-2):152-4. PubMed ID: 23932896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fas and Fas ligand: Expression and soluble circulating levels in bile duct carcinoma.
    Murakami M; Sasaki T; Miyata H; Yamasaki S; Kuwahara K; Chayama K
    Oncol Rep; 2004 Jun; 11(6):1183-6. PubMed ID: 15138553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating soluble Fas ligand in patients with gastric carcinoma.
    Tsutsumi S; Kuwano H; Shimura T; Morinaga N; Mochiki E; Asao T
    Cancer; 2000 Dec; 89(12):2560-4. PubMed ID: 11135216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum soluble Fas (CD95) and Fas ligand profiles in chronic kidney failure.
    Perianayagam MC; Murray SL; Balakrishnan VS; Guo D; King AJ; Pereira BJ; Jaber BL
    J Lab Clin Med; 2000 Oct; 136(4):320-7. PubMed ID: 11039853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity.
    Schneider P; Holler N; Bodmer JL; Hahne M; Frei K; Fontana A; Tschopp J
    J Exp Med; 1998 Apr; 187(8):1205-13. PubMed ID: 9547332
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma soluble Fas ligand concentration: decrease in elderly men and increase in patients with gastric carcinoma.
    Ichikura T; Majima T; Uchida T; Okura E; Ogawa T; Mochizuki H
    Oncol Rep; 2001; 8(2):311-4. PubMed ID: 11182046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical significances of serum soluble fas and soluble fas ligand in chronic hepatitis B].
    Jun EJ; Han JY; Sun HS
    Korean J Hepatol; 2006 Dec; 12(4):507-14. PubMed ID: 17237628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.